Tetra Bio-Pharma (TBPMF -1.9%) has received orphan drug designation for its treatment (Delta-9-Tetrahydrocannabinol) for hepatocellular carcinoma.
Shares are up 10.5% in Toronto.
Amgen gets orphan drug designation for anemia treatment
Amgen (NASDAQ:AMGN) has received an orphan drug designation for its Nplate (romiplostim) in treating aplastic anemia.
That will mean seven years’ market exclusivity if approved for the treatment.
Shares have been on a roll, up 12.2% over the past month and up 40.7% over the past six months.
FibroGen +6.3% as Leerink sees China price upside
FibroGen (NASDAQ:FGEN) is up 6.3% on healthy volume after a positive mention at SVB Leerink, which sees revenue upside coming from the latest word on China’s National Reimbursement Drug List.
The NRDL price for FibroGen’s roxadustat is likely to come in at 95.5 yuan/tablet, translating to about $177/month and $2,128/year – higher than analyst Geoffrey Porges’ expected $1,600/year, he says.
That higher price would likely mean a boost to the company’s value of $5/share, he writes.
Leerink has an Outperform rating and a Street-high price target of $84, currently implying 95% upside.
Sell-side analysts are Bullish on average, while Seeking Alpha authors are Neutral overall. The stock has a Quant Rating of Neutral.
Myovant +3.6% after Roivant share deal
Myovant Sciences (NYSE:MYOV) is up 3.6% in first action since disclosing in a filing that Roivant Sciences agreed to buy 3.5M shares of Myovant from Millennium Pharma.
That agreement came on Monday, according to the filing.
It brings Roivant’s stake in Myovant to 49.7%.
The shares came at $15 each, for a total outlay of $52.5M.
Xeris +5% after CEO/Chairman buys shares
Xeris Pharmaceuticals (NASDAQ:XERS) is up 5% in decent post-holiday volume after disclosing that Chairman/CEO Paul Edick bought 17,935 shares this week.
The Monday purchase came at an average price of $8.5466, marking a total outlay of about $153,283.
Shares have been rangebound in recent weeks, but are down 25.9% over the past quarter and are down nearly 50% YTD.
